科研之友
微信
新浪微博
Facebook
分享链接
摘要
BACKGROUNDNo studies have been performed comparing intravenous (IV) iron with transfused red blood cells (RBCs) for treating anemia during infection. In a previous report, transfused older RBCs increased free iron release and mortality in infected animals when compared to fresher cells. We hypothesized that treating anemia during infection with transfused fresh RBCs, with minimal free iron release, would prove superior to IV iron therapy. STUDY DESIGN AND METHODSPurpose-bred beagles (n=42) with experimental Staphylococcus aureus pneumonia rendered anemic were randomized to be transfused RBCs stored for 7days or one of two IV iron preparations (7 mg/kg), iron sucrose, a widely used preparation, or ferumoxytol, a newer formulation that blunts circulating iron levels. RESULTSBoth irons increased the alveolar-arterial oxygen gradient at 24 to 48hours (p=0.02-0.001), worsened shock at 16 hours (p=0.02-0.003, respectively), and reduced survival (transfusion 56%; iron sucrose 8%, p=0.01; ferumoxytol 9%, p=0.04). Compared to fresh RBC transfusion, plasma iron measured by non-transferrin-bound iron levels increased with iron sucrose at 7, 10, 13, 16, 24, and 48hours (p=0.04 to p<0.0001) and ferumoxytol at 7, 24, and 48hours (p=0.04 to p=0.004). No significant differences in cardiac filling pressures or performance, hemoglobin (Hb), or cell-free Hb were observed. CONCLUSIONSDuring canine experimental bacterial pneumonia, treatment of mild anemia with IV iron significantly increased free iron levels, shock, lung injury, and mortality compared to transfusion of fresh RBCs. This was true for iron preparations that do or do not blunt circulating free iron level elevations. These findings suggest that treatment of anemia with IV iron during infection should be undertaken with caution.
- 出版日期2017-10
- 单位NIH
